Abivax publishes a prospectus in the context of its capital increase and bonds offering
The issuer is solely responsible for the content of this announcement.
ABIVAX Abivax publishes a prospectus in the context of its capital increase and bonds offering Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Abivax publishes a prospectus in the context of its capital increase and bonds offering
The prospectus is composed of:
These documents are available on the websites of the Company (www.abivax.com) and/or on the website of the AMF (www.amf-france.org). ***** About Abivax (www.abivax.com) Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_. Contacts
This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions. Regulatory filing PDF file File: 210723_Abivax prospectus capital increase and bonds offering |
|
|
Language: | English |
Company: | ABIVAX |
5, Rue de La Baume | |
75008 Paris | |
France | |
E-mail: | [email protected] |
Internet: | www.abivax.de |
ISIN: | FR0012333284 |
Euronext Ticker: | ABVX |
AMF Category: | Inside information / Other releases |
EQS News ID: | 1221444 |
End of Announcement | EQS News Service |
|
1221444 23-Jul-2021 CET/CEST